ViroGin Biotech Co.,LtdViroGin Biotech Co.,Ltd

2015.9

Company Introduction

Project Introduction

Market Analysis

Mission And Plan

1

2

3

4

CO

NTEN

TS

Company Introduction

Project Introduction

Market Analysis

Mission and plan

1

2

3

4

CO

NTEN

TS

Introduction of the companyIntroduction of the company

• Name of the company: ViroGin Biotech Ltd

(Registered in Cayman Islands)

•Including two operating centers:

•Shenzhen ViroGin Biotech Ltd (in China)

•Vancouver ViroGin Biotech Ltd (in Canada)

Background of the companyBackground of the company

• Virogin Biotech is an early stage Biotech research company.

• The company has a very advanced research team led by Dr. William

Jia. The team has completed many world class research projects.

Especially in the field of anti-tumor medicine with breakthrough

technology.

• In addition to their world class research team, the company also has

a very strong management team with investors and shareholders’

interest on top of their mind.

Target of the companyTarget of the company

• Virogin will focus on the research of anti-tumor medicine—the

research of cancer-dissolving virus vaccine---VGH-X. On target to

apply for the anti-tumor medicine patent within a year.

Furthermore, we are collecting all necessary data for the first stage

clinical test in two to three years and seeking CFDA approval.

Core MemberCore Member

Company Introduction

Project Introduction

Market Analysis

Target And Plan

1

2

3

4

CO

NTEN

TS

Project BackgroundProject Background

• What is an oncolytic virus ？

An oncolytic virus is a virus that specifically replicates in tumor cells

and causes tumor cell lysis but does not affect normal cells. The technology

of molecular virology makes the viral genome modification and recombination

possible. A few years ago the largest US biopharmaceutical company

AMGEN purchased with one billion dollars the herpes simplex virus (HSV-1)

based oncolytic virus from a small UK company (OncoVex) ， and

successfully completed Phase III clinical trial in 2014. In April 2015 ， the

joint meeting of the FDA’s Cellular, Tissue, and Gene Therapies Advisory

Committee (CTGTAC) and Oncologic Drugs Advisory Committee (ODAC)

voted at 22:1 to approve the biologics license for the drug (T-Vec), and made

it the first oncolytic viral drug in the world.

Project BackgroundProject Background

• Oncolytic virus and tumor vaccine

The rapidly advancing tumor immunotherapy is to use various means to

stimulate anti-tumor activities of immune cells as well as to block tumor-

induced immune suppression. Oncolytic virus clinical trials showed that the

anti-tumor activities of oncolytic viruses are not only due to the direct tumor

cell lysis caused by the viruses, but also due to virally induced anti-immune

response to the tumor.

Project BackgroundProject Background

• Advances of Technology - Virogin Biotech

The combination of oncolytic virus and immune therapy will produce a huge

synergy, especially for the treatments of solid tumors.

1. Oncolytic viruses infect a large number of tumor cells and present viral

antigens efficiently on tumor cells, which greatly help the activation and recognition

of immune cells.

2. Oncolytic tumor cell lysis caused by the virus releases a large number of

endogenous proteins, some of which may be tumor neoantigens and recognized

by the immune cells to attack surrounding uninfected cells.

Project BackgroundProject Background

• Advances of Technology - Virogin Biotech

3. Oncolytic virus infection of the tumor cells dramatically change the tumor

microenvironment, resulting in destruction of vascular structure and a large amount

of immune cell infiltration.

4. In current immunotherapies, blockers of tumor immunosuppressors are

injected to the entire body and therefore may produce toxic side effects. However

the blockers of immune suppression carried by oncolytic viruses are expressed in

tumors and can greatly reduce the toxic side effects.

Project DetailsProject Details

• Oncolytic virus tumor vaccine VGH-X carrying immune-stimulating factor(s)

• In vitro validation of VGH-X anti-tumor activity

• In vivo validation of VGH-X anti-cancer activity

Company Introduction

Project Introduction

Market Analysis

Target And Plan

1

2

3

4

CO

NTEN

TS

Analysis of the marketAnalysis of the market

1

Current status of the

market

2

Comparison with the

current oncotytic

product ONCOVEX

3

Comparison with

current immune-

therapy medicine

4

The price advantage

of our product

Many oncolytic viruses are in the clinical stage and the study of immunization therapy of PD1/PD-L1 is very popular; however, there has been no PD1/PDL1 blockers are expressed by OVs in the clinic.

Our product will have better intratumoural dissemination and the immune-stimulating factor will have much stronger immune stimulating effect; therefore, it should have better clinical result.

Curing effect will be better and the side effect will be much lower.

The producing cost will be similar to PD1/PD-L1 antibody; however, our product will have better curing power; therefore, our product will have price advantage.

Company Introduction

Project Introduction

Market Analysis

Target And Plan

1

2

3

4

CO

NTEN

TS

Target of financingTarget of financing

The creation of the company

1

2

3

4Completing the first run of financing before August 2015

Completing U$ 8million of the second run of financing before July 2016

Expansion of our operation

Introduction of our investorsIntroduction of our investors

Shen Zhen Sangel asset management limited is a comprehensive investment

institute which specializes in venture capital and angel capital projects; it is

incubator of high tech. companies. Sangel bases itself upon the most promising

industries: Biotech, Medical facilities, Healthcare, Technology of life resource,etc.

GP Capital investment fund management company is the manager of

Shanghai development investment fund which was founded by Shanghai

international asset management group, Jiangsu Sagang investment group, Huatai

security limited company and Hengdian holding company. On December 28th 2012,

the fund successfully closed its first close-end fund which was over 9 billion Ren

Ming Bi---Chinese Yuan.

Johnson & Johnson has been a part of people's lives for 129 years and a valuable part of

their investments for approximately 70 years. Founded in 1886, we listed our shares on the

New York Stock Exchange for public investors in 1944.

During our history, we have built the most comprehensive base of health care businesses

in the world, generating approximately 70 percent of our revenues from No. 1 or No. 2 glob

al leadership positions in our respective markets.

Over the last 10 years, Johnson & Johnson stock generated a 8.3 percent total return for

investors compared to a 7.7 percent total return for the S&P 500.

Development PlanDevelopment Plan

0-9months

9-12months

13-30months

31-50months

Completing the

construction of

the virus

Completing OV

virus

construction and

initial tests and

applying patents

Completing IND

enabling and

submitting IND

Completing Phase

I clinical trial

Thank Thank

YouYou ！！Thank Thank

YouYou ！！Virogin Biotech Co.,Ltd